This article is more than 5 years old. Information may no longer be current.

Alcon files patent infringement suit against Teva

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

FORT WORTH, Texas — Alcon Inc. has filed suit against Teva Pharmaceuticals. Alcon has claimed patent infringement of Vigamox after Teva submitted an Abbreviated New Drug Application with the Food and Drug Administration to market a generic version, Alcon said in a press release.

Alcon licenses moxifloxacin, the active ingredient in Vigamox, from Bayer. Alcon's suit, filed jointly with Bayer, alleges Teva infringed on two Bayer patents and one Alcon patent.

Vigamox is used for the treatment of bacterial conjunctivitis caused by susceptible strains of microorganisms, according to the press release.